Lipocalyx Overview

  • Founded
  • 2011
  • Status
  • Acquired/​Merged
  • Employees
  • 5
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $7.89M
Latest Deal Amount

Lipocalyx General Information


Developer of drug-delivery technology designed to offer new generation transfection reagents. The company's technology focuses on creating novel polymer-based transfectants for oligonucleotides which have applications for siRNA transfection, a technology for gene silencing or knockdown, enabling doctors to get highly efficient, easy to use and low-toxic transfection reagents.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Primary Office
  • Weinbergweg 23
  • 06120 Halle
  • Germany
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Lipocalyx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 06-Jan-2020 $7.89M 00.000 Completed Generating Revenue
1. Seed Round 22-Sep-2011 Completed Startup
To view Lipocalyx’s complete valuation and funding history, request access »

Lipocalyx Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lipocalyx Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Goodvent Venture Capital Minority 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
IBG Beteiligungsgesellschaft Sachsen-Anhalt Venture Capital Minority 000 0000 000000 0
bmp Ventures Venture Capital Minority 000 0000 000000 0
To view Lipocalyx’s complete investors history, request access »